Paclitaxel drug page Clinical trials

Trials with Paclitaxel

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

36Trials
10Recruiting
33Countries
11.308Planned patients

Showing 1–20 of 36

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Recruiting Phase 2 260 patients NCT07492680

This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BM…

United States, Belgium, Canada, China and 8 more Jul 2026 – May 2032 Interventional
AK129 Combination Therapy for Advanced Solid Tumors
Recruiting Phase 1 230 patients NCT06943820

This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129 combinations f…

China May 2025 – May 2028 Interventional
ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies
Recruiting Phase 1/2 280 patients NCT07007559

Participants will continue study treatment until disease progression, death, unacceptable toxicity, participant request to stop treatment, investigator decision or study termination by the sponsor. Not all substudies may be active and/or …

United States Apr 2025 – Dec 2027 Interventional
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Recruiting Phase 1 214 patients NCT06839105

The purpose of this phase I clinical study was to evaluate the safety and tolerability of AWT020 monotherapy and combination with other antitumor therapies in patients with advanced malignancies

China Feb 2025 – Apr 2028 Interventional
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
Recruiting Phase 1 282 patients NCT06758557

This study is a multicenter, two-tumor, multi-cohort, dose-escalation and dose-expansion Phase Ib/II clinical trial of HB0025 combined with chemotherapy, consists of two phases: the dose escalation phase (Ib) and the dose expansion phase (…

China Jan 2024 – Feb 2026 Interventional
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Recruiting Phase 1 134 patients NCT06047379

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…

United States Nov 2023 – Aug 2027 Interventional
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Recruiting Phase 1 358 patients NCT05824975

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd…

United States, South Korea May 2023 – Apr 2027 Interventional
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Recruiting Phase 2 2.900 patients NCT05564377

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

United States, Puerto Rico Apr 2023 – Jul 2030 Interventional
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carci
Recruiting Phase 1 350 patients NCT05482893

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Pa…

United States Mar 2023 – Apr 2028 Interventional
A Study of NX-1607 in Adults With Advanced Malignancies
Recruiting Phase 1 345 patients NCT05107674

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

United States, United Kingdom Sept 2021 – Feb 2028 Interventional
Combined with: NX-1607
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ongoing, not recruiting Phase 1 340 patients NCT06561685

The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid …

United States, France, Germany, Japan and 2 more Sept 2024 – Oct 2027 Interventional
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Ongoing, not recruiting Phase 1 275 patients NCT06328738

The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemothe…

United States, Belgium, France, Italy and 3 more May 2024 – Jul 2028 Interventional
Study of INCB123667 in Subjects With Advanced Solid Tumors
Ongoing, not recruiting Phase 1 604 patients NCT05238922

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapi…

United States, France, Italy, Japan and 4 more Jul 2022 – Aug 2027 Interventional
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
Ongoing, not recruiting Phase 1 66 patients NCT05275777

This is an open label, lead in phase Ib dose confirmation study in patients with advanced solid tumors, followed by a phase II single arm study as neoadjuvant therapy in stage I-III HER2 negative breast cancer. Primary Objectives * To de…

Singapore May 2022 – Feb 2030 Interventional
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Ongoing, not recruiting Phase 1 193 patients NCT05307705

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA …

United States, Australia, Belgium, Canada and 7 more May 2022 – Dec 2026 Interventional
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
Ongoing, not recruiting Phase 3 205 patients NCT04444921

This phase 3 trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body (metastatic). Immun…

United States Nov 2020 – Mar 2027 Interventional
Combined with: CarboplatinNivolumab
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Ongoing, not recruiting Phase 1 702 patients NCT04644068

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

United States, Australia, Canada, China and 7 more Nov 2020 – May 2027 Interventional
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Ongoing, not recruiting Phase 1 320 patients NCT04495296

This is an open-label, multi-center, Phase I trial of TST001. Subjects with locally advanced or metastatic solid tumors will be enrolled. The study will consist of two parts: Part A is dose escalation and dose expansion phase for mono-ther…

China Aug 2020 – Dec 2026 Interventional
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Ongoing, not recruiting Phase 1 610 patients NCT04185883

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

United States, Australia, Austria, Belgium and 6 more Dec 2019 – Dec 2027 Interventional
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Ongoing, not recruiting Phase 1 350 patients NCT04083599

The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain ty…

United States, Denmark, France, Georgia and 7 more Sept 2019 – Jan 2027 Interventional

Where the recruiting trials are